AbbVie’s neuroscience division is projected to generate $12.7 billion in sales this year, marking a key shift away from its Humira‑centric model
Executive summary: AbbVie’s management disclosed that its neuroscience business is on track to deliver $12.7 billion in sales during 2026. The figure underscores a major revenue stream beyond Humira, reducing reliance on a single product and potentially boosting the company’s long‑term growth profile.
Who is involved: AbbVie executive leadership, the neuroscience division, and institutional investors tracking the company’s pipeline.
Likely next: AbbVie is expected to continue investing in neuroscience R&D, pursue additional regulatory approvals, and may explore complementary M&A to sustain the momentum.
AbbVie has highlighted its neuroscience franchise as a quiet but rapidly growing powerhouse, with management forecasting $12.7 billion in revenue for the current fiscal year. This signals a strategic pivot toward diversification as the company seeks to offset looming Humira patent expirations. The development could reshape AbbVie’s growth trajectory and influence investor sentiment toward the stock.
Timeline
- — Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year (Yahoo Finance)
- — AbbVie Defends Its Turf, But Leaves One Big Question Open (Yahoo Finance)
- — AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use (Yahoo Finance)
Analysis — what this means
Sectors affected
- Pharmaceuticals
- Neuroscience therapeutics
Historical parallels
- AbbVie’s post‑Humira shift parallels its 2026 Botox expansion, which moved a step closer to a fifth approved use (AbbVie’s Botox Just Got A Step Closer To A Fifth Use, Aug 10 2026).
Key entities
Sources
- Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year — Yahoo Finance
- AbbVie Defends Its Turf, But Leaves One Big Question Open — Yahoo Finance
- AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use — Yahoo Finance
Related cases
- Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
- AbbVie seeks EMA approval for subcutaneous risankizumab induction in Crohn’s disease, expanding its immunology portfolio
- Patent expirations on blockbuster drugs threaten $440 billion in pharma revenues, with Merck-MSD and AbbVie most exposed
- Healthcare stocks become a safe haven as investors exit tech